CLINICAL TRIAL: PHASE I TRIAL OF INTRAVENOUS FENRETINIDE (4-HPR) FOR PATIENTS WI

临床试验：针对 WI 患者静脉注射芬维A胺 (4-HPR) 的 I 期试验

• 批准号: 7982105
• 负责人: ALLEN S YANG
• 金额: $ 1.97万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982105
• 关键词: Adult; Biological Availability; Breast; Cell Line; Child; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Drug Formulations; Fenretinide; Funding; Grant; Hematologic Neoplasms; Institution; Intravenous; Intravenous Fat Emulsions; Malignant neoplasm of ovary; Neuroblastoma; Oral; Patients; Pharmaceutical Preparations; Phase I Clinical Trials; Research; Research Personnel; Resources; Safety; Serum; Source; Testing; Titrations; Toxic effect; United States National Institutes of Health; cytotoxicity; design; leukemia; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase I Trial of Intravenous Fenretinide (4-HPR) for patients with Hematologic Malignancies using an accelerated titration design. Fenretinide has been tested in oral formulation in treatment of breast and ovarian cancer in adults, and in neuroblastoma in children. Poor bioavailability of the oral drug precludes reaching serum levels shown to have direct tumor cytotoxicity for leukemia and lympoma cell lines. This phase I trial will assess safety, feasibilty, and toxicity of a new intravenous lipid emulsion formulation of fenretinide in patients with Hematologic Malignancies.

这个子项目是众多研究子项目之一